Patient Square Capital
Patient Square Capital reported 23 stocks worth $646M in its 13F filing for Q2 2026, filed Aug 12, 2026. Its largest holdings are ROIV (44.0%), RVMD (8.0%) and MIRM (4.7%). Compared with Q1 2026, the fund opened new positions in RVMD, UTHR and BNTX, added to MIRM, ABVX and ONC, trimmed ROIV, ARGX and BLTE and sold out of INSM, LEGN and NKTR.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  ROIV Roivant Sciences Ltd | $284M | 44.0% | 8M | −145K (−2%) | 8 of 8 | |
| 2 |  RVMD Revolution Medicines Inc | $51.7M | 8.0% | 276K | New position | 1 of 8 | |
| 3 |  MIRM Mirum Pharmaceuticals Inc | $30.5M | 4.7% | 261K | +31K (+13%) | 7 of 8 | |
| 4 |  ABVX Abivax SA | $27.5M | 4.3% | 207K | +85K (+70%) | 4 of 8 | |
| 5 |  ONC Beone Medicines Ltd | $25.7M | 4.0% | 90K | +9,478 (+12%) | 3 of 8 | |
| 6 |  PHVS Pharvaris N V | $23.2M | 3.6% | 671K | +178K (+36%) | 8 of 8 | |
| 7 |  ARGX Argenx SE | $21.3M | 3.3% | 23K | −14K (−37%) | 5 of 8 | |
| 8 |  UTHR United Therapeutics Corp Del | $20.1M | 3.1% | 37K | New position | 1 of 8 | |
| 9 |  BLTE Belite Bio Inc | $16.9M | 2.6% | 110K | −6,684 (−6%) | 2 of 8 | |
| 10 |  COGT Cogent Biosciences Inc | $16.4M | 2.5% | 425K | −171K (−29%) | 3 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 INSM Insmed Inc | $25.8M | 158K |
 LEGN Legend Biotech Corp | $17.9M | 990K |
 NKTR Nektar Therapeutics | $15.1M | 210K |
 CELC Celcuity Inc | $10.8M | 95K |
 MRK Merck & Co Inc | $9.6M | 80K |
🔒 Free account: see all 12.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 12, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Patient Square Capital 13F FAQ
What does Patient Square Capital own?
Patient Square Capital reported 23 stocks worth $646M in its 13F filing for Q2 2026, filed Aug 12, 2026. Its largest holdings are ROIV (44.0%), RVMD (8.0%) and MIRM (4.7%). The table above lists every position in the filing (the top 10 without an account).
What did Patient Square Capital buy and sell in Q2 2026?
Compared with Q1 2026: 6 new positions, 9 added to, 8 trimmed and 12 sold out. New positions include RVMD, UTHR and BNTX. It sold all of INSM, LEGN and NKTR.
When will Patient Square Capital file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Patient Square Capital's portfolio worth?
The Q2 2026 filing reports $646M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.